Australia's Rhythm Biosciences up on positive study results for breast cancer diagnostics

Rhythm Biosciences

21/09/2023 05:09

** Shares of medical diagnostics co Rhythm Biosciences
 RHY.AX  rise as much as 15% to A$0.345, their biggest intraday
pct gain since Aug. 23
        ** RHY at its highest level since Sept. 15
    ** Co says preliminary results from Agilex Stage 1 study
show positive results  
    ** Adds, identified four biomarkers, combinations that can
distinguish between patients with breast cancer and healthy
controls, with a 83% sensitivity and a 90% specificity
    ** Nearly 455,500 shares change hands, compared with 30-day
average volume of 177,596
    ** Stock down 69.7% YTD, as of last close, vs 1.7% increase
in benchmark S&P/ASX 200 index  .AXJO  

 (Reporting by Roshan Thomas in Bengaluru)
 ((Roshan.Thomas@thomsonreuters.com;))